Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 5
2004 1
2005 7
2006 10
2007 9
2008 16
2009 17
2010 22
2011 40
2012 29
2013 44
2014 48
2015 46
2016 50
2017 56
2018 48
2019 50
2020 69
2021 58
2022 57
2023 57
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

661 results

Results by year

Filters applied: . Clear all
Page 1
Type 2 diabetes.
Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Ahmad E, et al. Among authors: lim s. Lancet. 2022 Nov 19;400(10365):1803-1820. doi: 10.1016/S0140-6736(22)01655-5. Epub 2022 Nov 1. Lancet. 2022. PMID: 36332637 Review.
New Trends in Dyslipidemia Treatment.
Jang AY, Lim S, Jo SH, Han SH, Koh KK. Jang AY, et al. Among authors: lim s. Circ J. 2021 May 25;85(6):759-768. doi: 10.1253/circj.CJ-20-1037. Epub 2020 Nov 12. Circ J. 2021. PMID: 33177309 Free article. Review.
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, Tobe K, Yamauchi T, Lim S; STEP 6 investigators. Kadowaki T, et al. Among authors: lim s. Lancet Diabetes Endocrinol. 2022 Mar;10(3):193-206. doi: 10.1016/S2213-8587(22)00008-0. Epub 2022 Feb 4. Lancet Diabetes Endocrinol. 2022. PMID: 35131037 Clinical Trial.
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.
Ji L, Dong X, Li Y, Li Y, Lim S, Liu M, Ning Z, Rasmussen S, Skjøth TV, Yuan G, Eliaschewitz FG. Ji L, et al. Among authors: lim s. Diabetes Obes Metab. 2021 Feb;23(2):404-414. doi: 10.1111/dom.14232. Epub 2021 Jan 3. Diabetes Obes Metab. 2021. PMID: 33074557 Free PMC article. Clinical Trial.
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, Laverman GD, Lim SK, Di Tanna GL, Reich HN, Vervloet MG, Wong MG, Gansevoort RT, Heerspink HJL; DIAMOND investigators. Cherney DZI, et al. Among authors: lim sk. Lancet Diabetes Endocrinol. 2020 Jul;8(7):582-593. doi: 10.1016/S2213-8587(20)30162-5. Lancet Diabetes Endocrinol. 2020. PMID: 32559474 Clinical Trial.
Pulmonary Artery Strain Predicts Prognosis in Pulmonary Arterial Hypertension.
Zhong L, Leng S, Alabed S, Chai P, Teo L, Ruan W, Low TT, Wild JM, Allen JC, Lim ST, Tan JL, Yip JW, Swift AJ, Kiely DG, Tan RS. Zhong L, et al. Among authors: lim st. JACC Cardiovasc Imaging. 2023 Aug;16(8):1022-1034. doi: 10.1016/j.jcmg.2023.02.007. Epub 2023 Apr 12. JACC Cardiovasc Imaging. 2023. PMID: 37052561
661 results